China Merchants Securities Co., Ltd. provides securities investment and trading services to corporate, institutional, and individual clients in the People's Republic of China. The company operates through Wealth Management and Institutional Business, Investment Banking, Investment Management, and Investment and Trading segments. It offers investment consultancy, investment portfolio recommendation, sale of products, and assets allocation; capital-based intermediary services, including margin financing, securities lending, and stock pledge repo and stock repurchase transactions; investment research, sales and trading, prime brokerage, and other services for funds and insurance companies; and trades in stocks, funds, bonds, futures, and other derivatives. The company also provides investment banking services, including domestic and international equity financing, debt financing, equity and bond underwriting, structured financing, over the counter (OTC) listing, merger and acquisition, financial advisory, and other services; and investment management services comprising collective asset management, separately managed account, specialized asset management, and equity investment fund management. In addition, it engages in the trading of equity and fixed-income securities, commodities, foreign exchange, alternative investment, and other derivatives, as well as offers OTC financial products, market maker services, and insurance agency services. The company was founded in 1991 and is based in Shenzhen, the People's Republic of China.

China Merchants Securities Co., Ltd.

招商证券 is involved in securities and futures brokerage, underwriting, financial consulting, corporate financing, investment management, asset management, market research, and fund administration services. It has a strong research development team and offers a range of financial services.

招商证券

Law Practice

CMS, China | 1,249 followers on LinkedIn. CMS is one of the top 10 global law firms. With more than 5,000 professional legal and tax advisors in over 70 offices in more than 40 countries, we advise clients on both global and local matters and provide pragmatic and commercial advice.

CMS, China has been advising clients on doing business in China for more than 30 years.

Office Manager at CMS, China

Deborah Chen

Partner at CMS, China

Colin Liu JianLong

Corporate, Competition & Compliance

Aiping Bao

M&A & Competition

Kevin Wang

CMS, China

CMS runners from Shanghai Office joined the J.P. Morgan Corporate Challenge on 14 November 2024. As the tradition of the Corporate Challenge, it supports charities in countries where its events are held. This year, it supports a local non-profit organization Shanghai Yishe Public Welfare and Cultural Development Centre as the 2024 J.P. Morgan Corporate Challenge Shanghai beneficiary. #cmslaw #cmschina #JPMorganCorporateChallengeShanghai

On 19 October 2024, the State Council of the People’s Republic of China announced the Regulations on Export Control of Dual-Use Items which will take effect on 1 December 2024. Stephen Wu and Zhiwei Wang provided a summary of the new stipulations and some noteworthy aspects under these new regulations. Please read newsletter here: https://lnkd.in/dDyM7PJj #cmslaw #corporate #commercial #RegulationsonExportControlofDualUseItems

On 25 September 2024, the PRC Supreme People's Court promulgated the Interpretation on the Application of the Part on Tort Liability in the PRC Civil Code (I) (the "Interpretation"), which entered into effect on 27 September 2024. Dr. Ulrike Glueck , Michael Munzinger and Jean Tian provided a summary of key aspects of the Interpretation which may be encountered in daily practice, and which may be relevant for potential tort liabilities of companies operating in the PRC. Please click here to read more: https://lnkd.in/dxKF-Bfc #cmslaw #TortLiability #PRCCivilCode #Interpretation

On your radar | Key employment issues to be aware of internationally Quarterly horizon scanner informing your about important up and coming developments and what to about them. Click on the link to access the publication: https://lnkd.in/egbz4h48 The 26th edition covers 31 countries and among other these topics: - Platform worker protection - AI and employment - Tackling anonymous hate speech - Discrimination claims For tailored advice, contact our CMS Employment & Pensions Team. #cmslaw #CMSemployment #horizonscanner #EmploymentLaw #HR #AIEthics #WorkplaceSafety #compliance

The Supreme People's Court of the People's Republic of China has recently promulgated the Interpretation on Several Issues Concerning the Application of Law to the Trial of Cases of Disputes over Punitive Damages in Food and Drugs (“Interpretation”), taking effect from August 22, 2024. The Interpretation has 19 articles in total covering various aspects regarding punitive damages related to food and drug as prescribed in related laws. Nicolas Zhu and Laila Lu provided a brief introduction on punitive damages in the food sector. Please click here to read more: https://lnkd.in/dfNUrR-J #cms #cmslaw #lifesciences #PunitiveDamagesforFoodandDrugDisputes

On 30 September 2024, the State Council of China released the Regulations on Network Data Security Management (“Regulations”), which will come into effect on 1 January 2025. The Regulations are the first administrative-level legal instrument in China following the establishment of the basic framework of China’s three fundamental laws in the field of data protection. Panpan Tang and Daisy Lv provided a brief introduction. Please click here to read it: https://lnkd.in/dSGsNMSK #cms #cmslaw #Dataprotection #IP #compliance #NetworkDataSecurityManagement

On 19 July 2024, the National Medical Products Administration and the National Health Commission jointly issued the Announcement on the Temporary Import and Use of Clinically Urgent Medical Devices for Medical Institutions, with immediate effect. On 14 September 2024, Beijing Drug Administrative Authority, together with three other local departments, issued the Beijing Municipal Implementation Plan for Facilitating the Temporary Import of Clinically Urgent Use Medical Devices (Trial). Nicolas Zhu and Laila Lu provided a brief introduction on the temporary import of clinically urgent medical devices. Please see our newsletter here: https://lnkd.in/ezJyykjb #cms #cmslaw #lifesciences #TemporaryImportandUseofClinicallyUrgentMedicalDevices

On September 13, 2024, the Chinese government issued new polices on change of statutory retirement age of employees. China will take 15 years to progressively raise the statutory retirement ages of employees, for male employees from 60 to 63 and for female employees from 50 to 55 or from 55 to 58 depending on their job positions. The new policies will become effective on 1 January 2025. Jeanette Yu and Chase Chen have provided an introduction. Read it here: https://lnkd.in/d77hQFxq #cmslaw #PRCStatutoryRetirementAge #Employment

On 14 September 2024, the National Technical Committee 260 on Cybersecurity of Standardization Administration of China (“TC260”) released TC260-PG-20244A Practical Guide to Cybersecurity Standard - Guide for Identifying Sensitive Personal Information (v1.0-202409) (“Guide”). The Guide aims to facilitate companies to identify sensitive personal information by providing relevant identification rules alongside specific examples. Please see our newsletter with a brief introduction： https://lnkd.in/ekipmn8g #cms #cmslaw #dataprotection #IdentifyingSensitivePersonalInformation #GuidetoCybersecurityStandardGuide

Liwei Shen (Gilbert) provided an overview on Chinese Tax Regulation Update in August & September 2024. Please read it here: https://lnkd.in/dTWjzra8 #cms #cmslaw #PRCtax

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue							17.83B -	23.24B 30.34%			19.79B -
cost of revenue							2.65B -	3.69B 39.21%
gross profit							15.17B -	19.54B 28.79%			19.79B -
selling and marketing expenses							283.69M -
general and administrative expenses							7.54B -	9.67B 28.32%
selling general and administrative expenses							7.54B -	9.67B 28.32%
research and development expenses
other expenses	-8.81M -	8.72M 198.88%	57.59M 560.83%	66.16M 14.87%	2.36M 96.43%	6.72M 184.89%	2.28B 33,844.38%	3.15B 37.95%	4.17B 32.46%	1.49B 64.26%	-10.51B 805.67%
cost and expenses							9.82B -	12.82B 30.56%			10.51B -
operating expenses	3.43B -	5.37B 56.74%	11.49B 113.95%	5.24B 54.36%	6.21B 18.42%	5.76B 7.28%	9.82B 70.56%	12.82B 30.56%	15.24B 18.86%	10.14B 33.46%	10.51B 3.70%
interest expense						6.34B -	6.39B 0.84%	7.12B 11.33%
ebitda	3.86B -						9.18B -	11.78B 28.26%			8.75B -
operating income							8.74B -	11.30B 29.21%			9.28B -
depreciation and amortization						144.61M -	439.67M 204.05%	480.91M 9.38%	522.75M 8.70%		-533.93M -
total other income expenses net							30.90M -	12.23M 60.43%			-2.69M -
income before tax							8.77B -	11.31B 28.90%			9.28B -
income tax expense							1.46B -	1.81B 23.60%			533.93M -
net income	2.23B -	3.85B 72.70%	10.91B 183.29%	5.40B 50.47%	5.79B 7.08%	4.42B 23.52%	7.28B 64.57%	9.49B 30.34%	11.65B 22.69%	8.07B 30.68%	8.74B 8.32%
weighted average shs out	5.61B -	6.45B 15.01%	7.00B 8.50%	7.16B 2.33%	8.94B 24.93%	9.88B 10.47%	8.07B 18.27%	8.21B 1.72%	9.32B 13.43%	9.39B 0.76%	9.30B 0.89%
weighted average shs out dil	5.61B -	6.45B 15.01%	7.00B 8.50%	7.16B 2.33%	8.94B 24.93%	9.88B 10.47%	8.07B 18.27%	8.21B 1.72%	9.32B 13.43%	9.39B 0.76%	9.30B 0.89%
eps	0.40 -	0.60 50.00%	1.56 160%	0.75 51.92%	0.65 13.33%	0.45 30.77%	0.80 77.78%	1.06 32.50%	1.25 17.92%	0.86 31.20%	0.94 9.30%
epsdiluted	0.40 -	0.60 50.00%	1.56 160%	0.75 51.92%	0.65 13.33%	0.45 30.77%	0.80 77.78%	1.06 32.50%	1.25 17.92%	0.86 31.20%	0.94 9.30%

6009

COM:CMSCHINA

招商证券

Last Close

19.90

22/11 07:00

Market Cap

111.11B

Beta: -

Volume Today

34.44M

Avg: -

Preview